Abstract Details

Title Real life efficacy and tolerability of Teriflunomide: multicentre study in Galicia (TERIGAL 2018).

Topic Multiple Sclerosis

Presentation(s) P3 - Poster Session 3 (5:30 PM-6:30 PM)

Poster/Presentation
Number 15-085

Objective Our objetive is to describe our initial experience with Teriflunomide in terms of tolerance and clinical effectiveness after 2 years of treatment.

Background Teriflunomide is an oral formulation which was approved as first line option for the treatment of Relapsing-Remitent Multiple Sclerosis. Its efficacy and adverse events have been described in randomized controlled trials. Data for regular clinical practice are need. We have been using teriflunomide since july 2015.

Design/Methods All patients from 10 Clinical Hospitals in Galicia, Spain, who were prescribed Teriflunomide were included, regardless of time on treatment. Basics demographic, clinical data, disability (EDSS scale), number of relapses, number of Gd enhancing lesions on craneal MRI, adverse events and reasons for discontinuation under teriflunomide were reported.

Results 228 patients (67.5% woman) were reviewed, 39.9% naive, average age 43,9 years old (+-9,0), average anual relapse 0,65 (+-0,7), average EDSS 1,8 (+-1,5), average number Gd enhancing lesions 0.65 (+-1,3). 175 and 92 patients complied 12 and 24 months of treatment, respectively. Teriflunomide decrease average anual relapse 0.17 (+-0.4) and 0,21 (+-0,4) p< 0,05 at 1 and 2 year, disability was stable 1,8 (+-1,7) and 2,2 (+-1,8) p>0,05 at 1 and 2 year, and average number Gd enhanging lesions was 0,27 (+-0,6) and 0,23 (+-0,5) p<0,05, at 1 and 2 year. 74 (41,2%) and 27 (29%) experience adverse events at 1 and 2 year, most common gastrointestinal (16%), hair thinning (13,1%), elevation ALT (8,5%) and cephalea (4,5). 1 severe adverse event (elevation ALT). 18 and 18 patients stopped the treatment in the last 12 and 24 months respectively, 50% inneficacy.

Conclusions The efficacy of teriflunomide in real-life setting was demostrate by the stability in EDSS and reduce the number of relapses. Teriflunomide has been well tolerated by the majority of patients.

Authors/Disclosures
Antonio Pato PRESENTER	Antonio Pato has nothing to disclose.
Elena Alvarez Rodriguez	Elena Alvarez Rodriguez has nothing to disclose.
Daniel García Estévez	The institution of Daniel García Estévez has received research support from MERCK. The institution of Daniel García Estévez has received research support from ROCHE.
	No disclosure on file
María Rodríguez Rodríguez	No disclosure on file
Eva Costa Arpín	Eva Costa Arpín has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Merck Serono.
Ana Rodriguez Regal	Ana Rodriguez Regal has nothing to disclose.
Miguel Angel Llaneza Gonzalez, MD (Neurologia - Hospital Arquitecto Marcide)	Miguel Angel Llaneza Gonzalez, MD has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi . Miguel Angel Llaneza Gonzalez, MD has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis . Miguel Angel Llaneza Gonzalez, MD has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Miguel Angel Llaneza Gonzalez, MD has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Bristol Myers Squib. Miguel Angel Llaneza Gonzalez, MD has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck.
	No disclosure on file
	No disclosure on file
Ines Gonzalez	Ines Gonzalez has nothing to disclose.
	No disclosure on file
Jose Ramon Lorenzo Gonzalez, Sr., MD (Hospital POVISA)	Dr. Lorenzo Gonzalez has nothing to disclose.
	No disclosure on file

��ɫ��

��ɫ��